Loading…
← CockpitCompetitor Analysis › 6960.T Fukuda Denshi Co., Ltd.Open in the cockpit ↗

Fukuda Denshi Co., Ltd.6960.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Japanese maker of patient monitors, ECG machines and other diagnostic medical devices for hospitals and clinics.

≈ A smaller Japanese GE Healthcare (patient monitoring)Momentum neutral 42
Mkt cap
$1.84B
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$9.34M
20-day average traded
Fwd P/E
15.4×
forward earnings
ROIC−WACC
+6.4 pp
WACC 7.5%
Hurdle
-1 pp
Req g minus delivered
Next earnings
75 days
1 Feb 2027
Close · JPY¥10,250
1D0.0%
1W+2.8%
1M-5.3%
3M-12.3%
6M+3.5%
YTD+35.6%
1Y+50.5%
ATR %3.6%
52w lowhigh17.9% off high

What Fukuda Denshi does

Japanese maker of patient monitors, ECG machines and other diagnostic medical devices for hospitals and clinics.

Sells monitors and ECG machines through its own domestic sales and service network to hospitals, then earns follow-on income from maintenance and the electrodes, paper and sensors those machines use. Most sales are in Japan.

In one line: A smaller Japanese GE Healthcare (patient monitoring).

Products and services

  • Patient monitors
  • ECG machines
  • AED defibrillators

Customers

  • Hospitals
  • Clinics

Where it sits in the supply chain

  • Health care
  • Medical devices
  • Patient monitors, ECG, diagnostic…

What could go right

  • Hospital equipment replacement demand

What could go wrong

  • Hospital capex cyclicality

Moat: narrow (installed base, regulatory licence). Long-standing hospital equipment relationships and regulatory approvals support recurring replacement sales.

Headquarters: Kawasaki, Japan · Founded: 1939 · Employees: 3,497

Named competitors

Fukuda Denshi at a glance

Size Fukuda Denshi (6960.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.84B, the 514th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥10,250 on 18 Nov 2026.

Performance Over six months the shares gained 3.5%, against +1.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 0.1% over the last twelve months (peer median +14.5%); the operating margin is 19.0% (peer median 13.6%).

Valuation It trades at 15.4× forward earnings against a peer median of 25.1× (3rd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.4 points above its cost of capital (7.5% WACC).

Next results Next results expected around 1 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026Peer median 1026960.T 97
Six months, rebased to 100: Fukuda Denshi against the median of its 20 peers (local-currency closes).

Fukuda Denshi financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥140B¥140B¥139B¥140B¥135B
Revenue growth—0%-1%+4%—
Gross profit¥76.2B¥74.6B¥72.1B¥72.7B¥68.6B
EBITDA¥39.0B¥38.5B¥36.4B¥36.2B¥33.5B
Net income¥18.5B¥18.8B¥18.6B¥18.7B¥17.3B
Free cash flown/a¥10.1B¥20.5B¥10.4B¥11.2B
Capital expendituren/a¥19.9B¥12.9B¥14.1B¥12.5B
Total debt¥4.45B¥3.48B¥3.32B¥3.51B¥3.68B

Quarterly statements and history in the cockpit →

Fukuda Denshi competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%268ASKAN1066MEDPOLYMED7716CHEMMLMAT301363EMBLAKMTSINSP8086BONEXVCYTBFLY66993010876960.T6-month return →1-month return →
Up and to the right = strong over both horizons. Fukuda Denshi is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%20×40×60×268ASKAN1066MEDPOLYMED7716CHEMM301363EMBLAXRAYINSPBONEXVCYT66993010876960.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Fukuda Denshi is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%268ASKAN10667716LMAT301363EMBLAXRAYINSPBONEXVCYT66993010876960.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Fukuda Denshi is the large dot.

Fukuda Denshi competitors and peer comparison

Head to head with its named competitors (6960.T vs 6849.T vs GEHC vs 300760.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Fukuda Denshi 6960.T$1.84B+4%0%19%15.4×-1.6%
Nihon Kohden 6849.T$1.55B+3%0%7%18.8×-3.5%
GE HealthCare GEHC$37.8B+30%+7%14%15.6×5.0%
Shenzhen Mindray Bio-Medical Electronics 300760.SZ$33.6B+15%+5%28%27.3×1.0%
Draegerwerk AG & Co. KGaA DRW8.DE$2.13B+25%+5%7%10.2×-10.2%
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%

How Fukuda Denshi compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Fukuda Denshi against its 20 peers (data as of 18 Nov 2026)
Measure6960.TPeer medianRank in peer set
1-month return-5.3%-4.4%9th lowest of 21
6-month return+3.5%+1.5%10th highest of 20
Distance from 52-week high-17.9%-24.8%8th highest of 21
Revenue growth (TTM)+0.1%+14.5%3rd lowest of 21
Operating margin19.0%13.6%6th highest of 21
Forward P/E15.4×25.1×3rd cheapest of 18
Growth the price implies (Req g, 7 yrs)-1.6%13.2%3rd least demanding of 15
Growth delivered (Del g)-1.0%+13.5%lowest of 15
Hurdle (Req g minus delivered)-0.6 pp-9.6 pp7th most demanding of 15
ROIC minus cost of capital+6.4 pp+0.6 pp6th highest of 21
EV / EBITDA5.9×17.9×2nd cheapest of 16
Net debt / EBITDA-1.6×-0.8×5th least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%

Questions

Who are Fukuda Denshi's main competitors?
Named competitors: Nihon Kohden (6849.T), GE HealthCare (GEHC), Philips (private or unlisted), Mindray Bio-Medical Electronics (300760.SZ), Draegerwerk (DRW8.DE), Masimo (private or unlisted). The cockpit's measured peer set (industry) also includes Rigaku (268A.T), Molbio Diagnostics (MOLBIO.NS), SKAN (SKAN.SW), Shandong Weigao Group Medical Polymer (1066.HK), Medartis (MED.SW), Poly Medicure (POLYMED.NS).
Is Fukuda Denshi expensive compared with its peers?
On forward p/e it trades at 15.4× against a peer median of 25.1×, 3rd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Fukuda Denshi stock performed?
Over six months to 18 Nov 2026 the shares returned +3.5% against +1.5% for the median peer; over one year +50.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.